BAY 2599023 clinical trials

(19429) A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe hemophilia A

This study is testing a new gene therapy, called BAY 2599023, for adult men with severe haemophilia A. It aims to see how safe the treatment is and find the right dose. The goal is to help their bodies make more of the clotting factor they need.